ACTH Peptide Prophylaxis for Renal Disorder Progression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for renal disorders, such as acute kidney injury and chronic kidney disease, are inadequate in addressing the underlying etiology and delaying the progression of kidney impairment, with existing regimens primarily focusing on symptom alleviation and extending survival by only a few months.
Innovation Solution
Administration of adrenocorticotropic hormone (ACTH) peptides or fragments, such as ACTH1-39, to individuals at risk or with renal disorders, based on biomarker detection, to delay the onset or progression of renal damage and improve kidney function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for renal disorders are used, then symptom alleviation is achieved, but the progression of kidney impairment is not delayed and survival is extended by only a few months
Solution Approach 1:
The patent applies preliminary action by administering ACTH to patients before renal failure fully develops, based on detection of early biomarker changes. This proactive approach aims to prevent or delay the progression of kidney impairment rather than merely treating symptoms after damage has occurred, thereby extending survival beyond the current few months.
Solution Approach 2:
The patent implements feedback by using biomarker detection (such as changes in serum creatinine, BUN, or other renal function markers) to monitor kidney health status and adjust ACTH treatment accordingly. This closed-loop system allows for timely intervention when early signs of renal impairment are detected, improving treatment effectiveness and extending survival.
2Duration of action of moving object
If ACTH is administered to individuals at risk of renal disorders, then the onset or progression of renal damage is delayed, but early detection of at-risk individuals is required
Solution Approach 1:
The patent applies preliminary action by implementing routine biomarker screening to identify individuals at risk of renal disorders before significant kidney damage occurs. This early detection enables timely administration of ACTH therapy to delay the onset or progression of renal damage, transforming a difficult detection problem into a manageable screening process.
3Duration of action of moving object
If ACTH treatment addresses underlying causes of kidney impairment, then long-term survival may be achieved, but the mechanism of action must be effective against the root etiology
Solution Approach 1:
The patent implements feedback by continuously monitoring biomarkers that reflect both the underlying etiology and the response to ACTH treatment. This allows for assessment of whether the treatment is effectively addressing the root cause of kidney impairment and adjustment of therapy to maintain long-term survival benefits.
Solution Approach 2:
The patent applies parameter changes by modifying physiological parameters through ACTH administration, such as altering cortisol levels or other hormonal pathways that may be involved in the underlying etiology of kidney impairment. By changing these key parameters, the treatment aims to address the root cause rather than merely managing symptoms.
Data Source
AI summary
Provided herein are methods for prophylactic treatment of renal disorders comprising administration of adrenocorticotropic hormone (ACTH), or fragment, analog, complex or aggregate thereof, or any combination thereof, to an individual suspected of having, predisposed to, or at risk of developing a renal disorder.